Investigating Lysosomal Storage Diseases in Minority Groups
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- O & O Alpan LLC
- Enrollment
- 20,000
- Locations
- 1
- Primary Endpoint
- Number of patients identified with lysosomal storage disorders
Study Overview
Brief Summary
Although lysosomal storage disorders, such as Fabry disease, Gaucher disease, and Pompe disease, represent serious challenges in the healthcare system, no study has yet investigated the prevalence of these diseases in the US. Frequently, patients show progressive worsening of symptoms for several years before they get diagnosed. Since many of these diseases can be managed therapeutically, it is important to identify and treat patients in order to avoid organ damage. The investigators aim to undertake a screening study that identifies undiagnosed patients with lysosomal storage disorders and determine the prevalence of these diseases with special focus on underrepresented minority groups.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 1 Day to 100 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age
- •Subject is managed by a physician in the Washington, D.C metro area
- •Subject is getting blood work as part of standard clinical care and there is at least 60 uL blood remained in a tube after all clinical tests were run
Exclusion Criteria
- •Absolute contraindication for blood drawing
- •Subject cannot be traced back by the referring physician upon a positive screening result
Outcomes
Primary Outcomes
Number of patients identified with lysosomal storage disorders
Time Frame: 2 years
Secondary Outcomes
No secondary outcomes reported